Certara, Inc. · NASDAQ:CERT
Certara — Technical Presentation (March 2014)
46 slides from Certara's technical presentation, Mar 25, 2014
Slide 1: Quantitative and Systems Pharmacology Approaches for the Development of Oncology Drugs
Quantitative and Systems Pharmacology Approaches for the Development of Oncology Drugs Karen Rowland Yeo, PhD Senior Scientific Advisor and Scientific Consultant Simcyp Limited, part of Certara Tuesday, 25 March 2014 We will begin at 11AM EDT – New York (8AM San Francisco, 4PM London, 5PM Paris) Eve
Slide 2: Today's Presenter
Today’s Presenter Dr. Karen Rowland Yeo • Senior Scientific Advisor and Principal Consultant • Helped develop and implement models within the Simcyp Simulator, which links the processes of drug discovery and development using simulations in virtual patient populations. • Heavily involved in Consulta
Slide 3: Outline
Outline •Introduction to PBPK modelling •System and drug related parameters •Integration of inter-individual variability •Application of PBPK modelling in drug development •Case study involving oncology drugs © Copyright 2012 Certara, L.P. All rights reserved. 3
Slide 4: PBPK Modelling & the Predict, Learn, Confirm Paradigm
PBPK Modelling & the “Predict, Learn, Confirm” Paradigm A. Intrinsic/extrinsic Factors B. PBPK Model components System component Drug-dependent EXTRINSIC (drug-independent) component Smoking Environment Lung INTRINSIC ADME, PK, PD and Pregnancy Rapidly perfused MOA Race organs Organ Dysfunction Diet
Slide 5: Regulatory Submissions Involving PBPK Modelling
Regulatory Submissions Involving PBPK Modelling Submissions according to area of application Submissions according to sponsor versus FDA activity © Copyright 2012 Certara, L.P. All rights reserved. Huang et al. J Pharm Sci, 2013
Slide 6: Separating Systems & Drug Information
Separating Systems & Drug Information Systems Drug Trial Data Data Design Age MW Weight LogP Dose Tissue Volumes pKa Route Tissue Composition Protein Binding Frequency Cardiac Output BP ratio Co-administered Drugs Tissue Blood Flows In vitro data: Populations [Plasma Protein] Metabolism Permeability
Slide 7: Model Selection
Model Selection Lumped minimal model OR Full PBPK Model Lung PO Small Intestine Generic Adipose ka Bone Single Adjusting Portal Vein Compartment Brain (SAC) Heart Arterial Venous Blood Kidney Blood kout kin Muscle Skin Systemic Liver Liver IV Compartment Spleen Portal Vein Gut IV Dose EHC PO Dose Fi
Slide 8: The Challenge of Population Variability
The Challenge of Population Variability Environment Disease Genetics © Copyright 2012 Certara, L.P. All rights reserved.
Slide 9: The Complexity of Covariates
The Complexity of Covariates Genotypes (Distribution in Population) Renal Function Body Ethnicity Disease Fat Serum Creatinine Sex Age (Distribution in Population) (Distribution in Population) Height Brain Body Volume Heart Surface Volume MPPGL Area HPGL Weight S9PPGL CPPGL Cardiac Cardiac Liver Out
Slide 10: Organs/Tissue Distributions
Organs/Tissue Distributions Frequency Frequency Size of Liver Size of Lungs Frequency Size of Stomach Frequency Size of GI Tract Frequency Size of Heart © Copyright 2012 Certara, L.P. All rights reserved.
Slide 11: Monte Carlo (MC) versus Correlated Monte Carlo (CMC)
Monte Carlo (MC) versus Correlated Monte Carlo (CMC) A randomly generated Randomly generated subjects subject using MC sampling using CMC sampling © Copyright 2012 Certara, L.P. All rights reserved.
Slide 12: Case Study – Drug Y
Case Study – Drug Y Drug Y is being developed for the treatment of various cancers. In vitro experiments indicate that Drug Y is mainly metabolised by cytochrome P450 3A4 to the major metabolite, a mono N-de- methylated product (M1). Further in vitro data (IC50 shift and CYP3A4 inactivation paramete
Slide 13: Application of PBPK Modelling - Strategy
Application of PBPK Modelling - Strategy Everolimus and Drug Y (M1) Jones & Rowland Yeo, CPT: Pharmacometrics & Systems Pharmacology (2013) © Copyright 2012 Certara, L.P. All rights reserved.
Slide 14: Input Data for Everolimus
Input Data for Everolimus Everolimus Reference MW 958.22 log P 7.4 DrugBank (ChemAxon) Compound type Neutral pKa n/a B:P 3.57 Kirchner et al. (2004) fu 0.265 Kirchner et al. (2004) Vss (L/kg) 15.4 Predicted fa 1 Assumed ka (h-1) Extrapolated from in vivo data 3.2 Kovarik et al. (2002); Kovarik et al
Slide 15: Prediction of Everolimus Exposure in Healthy Volunteers (HV)
Prediction of Everolimus Exposure in Healthy Volunteers (HV) • A full PBPK model assuming first order absorption and physiological parameters for the HV population were used for all simulations. • Trial design: 12 subjects (2 female) aged 19 to 45 years (Kovarik et al., 2005) and 16 subjects (5 fema
Slide 16: Prediction of Time Dependent Inhibition
Prediction of Time Dependent Inhibition [S] [P] Rsyn [E·S] (zero order rate) [E] Kdeg (first order [E·I] rate) [I] kinact [PI] Drug Y [E·MI] M1 Accelerated Deactivation Rowland Yeo et al., Eur J Pharm Sci 2011 © Copyright 2012 Certara, L.P. All rights reserved.
Slide 17: Prediction of DDIs in Healthy Volunteers - Erythromycin
Prediction of DDIs in Healthy Volunteers - Erythromycin • The trial design used for simulation of the blood concentration-time profiles of everolimus in HV during co-adminstration of erythromycin was based on the study described by Kovarik et al. (2005). • Sixteen subjects (5 female) aged 23 to 37 y
Slide 18: Oncology Population – Age Related Changes
Oncology Population – Age Related Changes 800 Oncology 600 400 Renal Function 200 0 Serum Creatinine Age Plasma Proteins (Distribution in Population) Height Body Surface Area Weight MPPGL HPGL Cardiac Cardiac Liver Output Index Volume Liver Intrinsic Weight Clearance © Copyright 2012 Certara, L.P. A
Slide 19: Oncology Population - Impact of Disease on Protein Binding
Oncology Population - Impact of Disease on Protein Binding PT [P] fu HV 0 0.5 1 1.5 AAG levels (g/L) PT [P] fu HV 0 20 40 60 Albumin levels (g/L) © Copyright 2012 Certara, L.P. All rights reserved. 19
Slide 20: Prediction of Everolimus Exposure in Patients
Prediction of Everolimus Exposure in Patients • The trial design used for simulation of the blood concentration-time profiles of everolimus in patients was based on the study described by O’Donnell et al. (2008). • Four patients (2 female) and 6 patients (3 female) aged 18 to 80 years with advanced
Slide 21: Model Development for Everolimus and Drug Y and M1
Model Development for Everolimus and Drug Y and M1 Developed and validated model for everolimus in HV and patients Validated DDI prediction of everolimus in HV Developed and validated model for Drug Y and M1 in HV and patients Model was applied prospectively to help with the design of DDI study with
Slide 22: Development of Model for Drug Y and M1
Development of Model for Drug Y and M1 DRUG Y 1- fa Faeces Gut Lumen Oral Dose M1 fa 1- FG(m) 1- FG Metabolites M1 Metabolites Gut Wall Gut Wall Metabolite Portal Vein Portal Vein C(m)PV CPV Non –M1 Metabolites FG (m) FG QPV QPV QPV QPV QHA QHA Systemic FH (m) FH Systemic Liver M1 Liver Compartment
Slide 23: Complex Interactions: Auto-inhibition and TDI
Complex Interactions: Auto-inhibition and TDI Auto-inhibition of CYP3A4 by M1 TDI of CYP3A4 by M1 Auto-inhibition of CYP3A4 by Drug Y TDI of CYP3A4 by Drug Y EVEROLIMUS Sub Y DRUG M1 TDI of CYP3A4 by Drug Y and M1 TDI of CYP3A4 by Drug Y and M1 Prediction of DDI with everolimus was used to optimise
Slide 24: Background for Drug X
Background for Drug X •CYP3A4 substrate •Competitive inhibitor of both CYP3A4 and CYP2C8 •Time dependent inhibitors of CYP3A4 (both parent and primary metabolite) © Copyright 2012 Certara, L.P. All rights reserved. 24
Slide 25: In Vitro Data for Drug X
In Vitro Data for Drug X •Metabolic data for HLM, hepatocytes and rCYPs •fmCYP3A4 (70-80%) •fu – for a range of concentrations •MW, log P, B:P ratio, pKa •Caco-2 permeability data •Inactivation data for CYP3A4 (kinact and KI) © Copyright 2012 Certara, L.P. All rights reserved. 25
Slide 26: Drug X – Clinical Study Data in HV
Drug X – Clinical Study Data in HV • Objectives – Safety, tolerability, PK and PD following single and repeat oral dosing – Food effect – Drug-drug interaction: effect of CYP3A4 inhibition • 4-part study Part 1: Single Part 2: Multiple Part 3: Food Part 4: Drug Ascending Dose Ascending Dose Effect I
Slide 27: Development of Model for Drug X and M1
Development of Model for Drug X and M1 DRUG X 1- fa Faeces Gut Lumen Oral Dose M1 fa 1- FG(m) 1- FG Metabolites M1 Metabolites Gut Wall Gut Wall Metabolite Portal Vein Portal Vein C(m)PV CPV Non –M1 Metabolites FG (m) FG QPV QPV QPV QPV QHA QHA Systemic FH (m) FH Systemic Liver M1 Liver Compartment
Slide 28: Prediction of Time Dependent Inhibition
Prediction of Time Dependent Inhibition [S] [P] Rsyn [E·S] (zero order rate) [E] Kdeg (first order [E·I] rate) [I] kinact [PI] Drug X [E·MI] M1 Accelerated Deactivation Rowland Yeo et al., Eur J Pharm Sci 2011 © Copyright 2012 Certara, L.P. All rights reserved.
Slide 29: Model Development – Single Dose
Model Development – Single Dose Drug X M1 Simulated (lines) and observed (circles) mean plasma concentration-time profiles of Drug X after a single oral dose. The grey lines represent the outcomes of simulated individual trials (10 x 9) and the solid black line is the mean data for simulated the pop
Slide 30: Model Development – Multiple Dosing
Model Development – Multiple Dosing Drug X Drug X – last day of dosing Simulated (lines) and observed (circles) mean plasma concentration-time profiles of Drug X after a single oral dose on day 1 followed by twice daily (BID) dosing on days 2 through 13 and a single dose on day 14. The grey lines re
Slide 31: Complex Drug Drug Interaction
Complex Drug Drug Interaction TIME DEPENDENT INHIBITION COMPETITIVE INHIBITION Drug X M1 Ketoconazole AUTO-INHIBITION © Copyright 2012 Certara, L.P. All rights reserved.
Slide 32: Model Validation – DDI Study with Ketoconazole
Model Validation – DDI Study with Ketoconazole Predicted and observed (n=16) median AUC ratios after a single oral dose of Drug X administered on the 4th day of 5 days of dosing of ketoconazole (200 mg BID). © Copyright 2012 Certara, L.P. All rights reserved. 32
Slide 33: Model Application – DDI Study with Ketoconazole; MD versus SD of Drug X
Model Application – DDI Study with Ketoconazole; MD versus SD of Drug X SD – 2X mg Drug X Control AUC ratio – 4.2 fmCYP3A4 – 80% Plus ketoconazole MD – 2X mg Drug X AUC ratio – 3.5 fmCYP3A4 – 70% © Copyright 2012 Certara, L.P. All rights reserved. 33
Slide 34: Model Application – DDI Study with Ketoconazole and Fluconazole
Model Application – DDI Study with Ketoconazole and Fluconazole Strong versus weak inhibitor Ketoconazole Fluconazole X mg BID Drug X 4.1 2.2 5X mg BID Drug X 3.5 2.2 25X mg BID Drug X 2.4 1.8 © Copyright 2012 Certara, L.P. All rights reserved. 34
Slide 35: Statements on PBPK Labelling
Statements on PBPK Labelling © Copyright 2012 Certara, L.P. All rights reserved.
Slide 36: Model Application – Prospective Prediction of DDI Study with Midazolam
Model Application – Prospective Prediction of DDI Study with Midazolam Midazolam Midazolam Plus Control Drug X Ratio Cmax AUC Cmax AUC Cmax AUC Trial (n=16) ng/ml ng/ml.h ng/ml ng/ml.h 1 6.1 28 17 197 2.8 7.0 2 4.9 20 11 80 2.3 3.9 3 5.1 23 11 95 2.1 4.2 4 4.7 21 14 154 2.9 7.2 5 4.3 19 12 131 2.7 6
Slide 37: Application of PBPK Modelling – Oncology Patients
Application of PBPK Modelling – Oncology Patients Jones & Rowland Yeo, CPT: Pharmacometrics & Systems Pharmacology (2013) © Copyright 2012 Certara, L.P. All rights reserved.
Slide 38: Impact of Cytokines on Drug Metabolising Enzymes
Impact of Cytokines on Drug Metabolising Enzymes o Cytokine levels are elevated in a number of inflammatory disease conditions, infections and in cancers o Decreased CYP activities including CYP3A4 have been observed following exposure to cytokines/cytokine modulators observed in vitro Suppressed Cy
Slide 39: In vitro systems to study cytokine suppression of CYPs
In vitro systems to study cytokine suppression of CYPs • Hepatocyte cultures • Co-cultures of hepatocytes and Kupffer cells Time dependent suppression of CYP 3A4 activity by IL-6 in human hepatocytes Time point EC50 Emax Emin (pg/ml) (% of untreated (% of untreated cells) cells) 48 h 56.3 84.1 41.6
Slide 40: Distribution of IL-6 in patients (Meta-analysis)
Distribution of IL-6 in patients (Meta-analysis) 10000 1000 IL-6 (pg/mL) 100 About 50–70% of these two populations IL-6 (pg/mL) exhibited an average systemic IL-6 levels 10 of 50–500 pg/ml. 1 0.1 Healthy RA Post-surgery 60 60 RA Post-surgery Percentage of population Percentage of population 50 50 40
Slide 41: Clinical Consequences of Increased IL-6
Clinical Consequences of Increased IL-6 o 28% reduction in midazolam clearance observed for cancer patients versus healthy volunteers (Bell, 2013). ↑ Drug Clearance Patients with inflammation, infection or cancer Elevated cytokines Drug (IL-1, IL-6, TNF, IFN, etc) ↓ CYP450 Adapted from Morgan, Clin
Slide 42: Oncology Population – Age Related Changes
Oncology Population – Age Related Changes 800 Oncology 600 400 Renal Function 200 0 Serum Creatinine Age Plasma Proteins (Distribution in Population) Height Body Surface Area Weight MPPGL HPGL Cardiac Cardiac Liver Output Index Volume Liver Intrinsic Weight Clearance Cheeti et al., 2012 © Copyright
Slide 43: Oncology Population - Impact of Disease on Protein Binding
Oncology Population - Impact of Disease on Protein Binding PT [P] fu HV 0 0.5 1 1.5 AAG levels (g/L) PT [P] fu HV 0 20 40 60 Albumin levels (g/L) Cheeti et al., 2012 © Copyright 2012 Certara, L.P. All rights reserved. 43
Slide 44: Model Validation – Multiple Dosing in Oncology Patients
Model Validation – Multiple Dosing in Oncology Patients Drug X M1 Simulated (lines) and observed (circles) mean plasma concentration-time profiles of Drug X after multiple dosing. The grey lines represent the outcomes of simulated individual trials (10 x 16) and the solid black line is the mean data
Slide 45: Model Application – DDI Study with Ketoconazole
Model Application – DDI Study with Ketoconazole Dose Dependent AUC Ratio X mg SD Drug X 4.1 Observed data in HV 2.5X mg BID Drug X 1.5 Prediction in patients 7.5X mg BID Drug X 1.3 Prediction in patients X mg QD Drug X 7.5X mg BID Drug X Active CY3A4 remaining after dosing of drug X Active CY3A4 rem
Slide 46: Contacts & Follow-Up: Thank you!
Contacts & Follow-Up: Thank you! Americas Telephone (US): 888-708-7444 Telephone (Intl): +1-919-852-4685 Email: sales@certara.com Europe Telephone: +33 1 56 95 17 10 Email: sales@certara.com India Telephone: +91 984 500 6625 Email: sales@certara.com Japan Telephone: +81 (0)50-3786-9898 Email: sales@